Wellgistics Health, Protega Pharmaceuticals collaborate for ROXYBOND

Wellgistics Health (WGRX) announced that its wholly owned subsidiary, Wellgistics is collaborating with Protega Pharmaceuticals. Protega is a specialty pharmaceutical company that launched ROXYBOND, an FDA-approved abuse-deterrent immediate-release opioid pain medication in the U.S. The collaboration is meant to support pharmacist education on abuse-deterrent pain management options and regulatory compliance as well as increase patient access to ROXYBOND for appropriately prescribed patients. The relationship will support education to these pharmacies and help provide distribution of ROXYBOND to appropriately prescribed patients, particularly in underserved and rural areas where Wellgistics’ independent pharmacy clients play a critical role in patient care.